International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 6.4.2020
The Pandemic, National Crises, and Racial Health Disparities
This week America faced twin crises—a continuing pandemic and massive protests against racial and institutional inequalities. Sadly, COVID-19 is impacting Black Americans disproportionately and the reasons for that are the subject of a congressional briefing today. IMF Chairman Dr. Brian G.M. Durie also spotlights new research examining the coronavirus in people living with myeloma and MGUS. Bottom line: safety measures need to continue.
COVID-19 Food Assistance Program
If you are in need of assistance with grocery bills during the pandemic, there are programs available to help. This program, made possible with support by Bristol-Myers Squibb, “supports patients with cancer, multiple sclerosis or rheumatoid arthritis who are unable to afford or access food or nutritional needs due to COVID-19.”
Sarclisa (isatuximab) Approved in Europe for Relapsed Refractory Multiple Myeloma
European Commission (EC) approved Sarclisa® (isatuximab) in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.
IRS Allows You to Adjust Some Healthcare Benefits Midyear
If you have set aside pre-tax wages for your flexible spending account to be allocated to healthcare or dependent care, the IRS has announced that you may be able to add, drop, or alter some of your benefits midyear. Your employer must allow these changes though. Learn more about this change from the IRS.
Calling All Researchers: Submit Your Grant Applications
The Brian D. Novis Research Grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2021 grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline to receive the applications is Saturday, August 1, 2020.
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
This Week’s Question:

COVID-19 FAQ #13: Is it safe for myeloma patients to resume in-person doctors' visits?
Watch Now
Clinical Trials

OCEAN Trial (Now Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Search the Myeloma Matrix 2.0

Smart Patients: Join the Conversation
Upcoming Events
IMF Patient & Family Webinar Replay
Myeloma and Coronavirus

Hawaiian Vacation Raffle
Kailua-Kona, Hawaii

Hatfield Hike
Appalachian Trail

Click here to see all events

We Thank Our Sponsors:

Amgen, Bristol-Myers Squibb, Genentech, GSK, Sanofi-Genzyme, and Takeda Oncology
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page